Company Encyclopedia
View More
Lipella Pharmaceuticals
LIPO.US
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
1.906 T
LIPO.USMarket value -Rank by Market Cap -/-
Valuation analysis
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
- P/E
- Price
- High
- Median
- Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
- P/B
- Price
- High
- Median
- Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
- P/S
- Price
- High
- Median
- Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
- Dividend Yield
- Price
- High
- Median
- Low
Institutional View & Shareholder
Analyst Ratings
- Price--
- Highest--
- Lowest--
News
View More